Applied Innovation,
Improved Products,
Better Life.
ST. LOUIS, MO – October 22, 2025
Gateway Pharma announced the successful completion of Phase 1 clinical trial for Metronidazole Delayed-Release (DR) Capsules, a QIDP-designated candidate for Clostridioides difficile infection (CDI).​
​
-
Low Systemic Exposure
-
High Fecal Concentrations
-
No adverse events reported
Our Mission
Innovating site-specific delivery of antibiotics to combat antibiotic resistance threats to the United States and the World.
BioSTL Award in 2018 Venture Showcase
July, 2023 – Gateway Pharma raised $300K co-development funds to move Metronidazole 505(b)(2) product forward into Phase 1 clinical study.
September, 2020 – We received the NIH NIAID Pre-Clinical Service Award on GMP manufacturing of Metronidazole Delayed-Release Capsules for treating Clostridium difficile infection.
​August, 2018 – We received the NIH SBIR Phase I grant on Metronidazole Colon-Delivery for treating Clostridium difficile Infection.
​
November, 2018 – Gateway won the BioSTL Award on the 10th Startup Connection Venture Showcase in St. Louis.